logo
Loading...
Addition of immune checkpoint inhibitor to standard of care chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis
Medicine and HealthExploration of Targeted Anti-tumor Therapy

Addition of immune checkpoint inhibitor to standard of care chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis

R. Srinivasmurthy, J. Ta, et al.

Research conducted by Ramaditya Srinivasmurthy, Jason Ta, Sharif Afifi, Taimur Khalid, Hazem Aboaid, Rishi Kumar Nanda, Daniel Thomas Jones, Kenny Do, Kevin Nguyen, Karina Fama, Sarah Aamer, Yin Mon Myat, Jo-Lawrence Bigcas, and Kyaw Zin Thein examines whether immune checkpoint inhibitors enhance standard chemoradiotherapy for locally advanced nasopharyngeal carcinoma. Across three randomized trials involving 1,022 patients, the combination significantly improved disease-control outcomes without broadly increasing chemoradiotherapy-associated toxicity, although immune-related adverse events rose and longer follow-up is needed to establish an overall survival benefit.... show more
Abstract
Background: Preliminary findings were previously published as a conference abstract. Immune checkpoint inhibitors (ICIs) have demonstrated activity in nasopharyngeal carcinoma (NPC), but their efficacy and safety when integrated with standard chemoradiotherapy (CRT) for locally advanced NPC remain under investigation. This study systematically reviewed and meta-analyzed randomized controlled trials evaluating the efficacy and safety of adding ICIs to standard CRT-based treatment in locally advanced NPC. Methods: MEDLINE and EMBASE were searched from inception through September 1, 2025, for English-language phase II or III randomized controlled trials evaluating ICIs plus standard therapy. Eligible outcomes included progression-free/event-free survival (PFS/EFS), overall survival (OS), distant metastasis-free survival (DMFS), locoregional recurrence-free survival (LRFS), and safety outcomes. Hazard ratios (HRs) were pooled with the generic inverse variance method, while adverse-event risk ratios (RRs) were pooled with the Mantel-Haenszel method. Fixed-effect models were used, and heterogeneity was assessed with I² statistics. Results: Three trials randomized 1,022 patients: CONTINUUM (n = 423), DIPPER (n = 450), and a phase II toripalimab trial (n = 149). The pooled safety population included 998 patients. Compared with standard treatment alone, ICI-containing treatment significantly improved PFS/EFS (HR 0.54; 95% CI 0.40–0.72; P < 0.0001), DMFS (HR 0.52; 95% CI 0.36–0.75; P = 0.0005), and LRFS (HR 0.47; 95% CI 0.31–0.71; P = 0.0003). OS favored ICIs but was not statistically significant (HR 0.77; 95% CI 0.49–1.20; P = 0.24). ICIs increased immune-related adverse events, whereas most CRT-associated locoregional and hematologic toxicities were not significantly increased. Discussion: Adding ICIs to standard CRT-based therapy significantly improved disease-control outcomes without broadly worsening the overall CRT-associated toxicity profile. Longer follow-up is required to determine whether these early disease-control benefits translate into a statistically significant OS advantage.
Publisher
Exploration of Targeted Anti-tumor Therapy
Published On
Sep 28, 2026
Authors
Ramaditya Srinivasmurthy, Jason Ta, Sharif Afifi, Taimur Khalid, Hazem Aboaid, Rishi Kumar Nanda, Daniel Thomas Jones, Kenny Do, Kevin Nguyen, Karina Fama, Sarah Aamer, Yin Mon Myat, Jo-Lawrence Bigcas, Kyaw Zin Thein
Tags
Nasopharyngeal carcinomaImmune checkpoint inhibitorsChemoradiotherapyProgression-free survivalDistant metastasis-free survivalLocoregional recurrence-free survivalMeta-analysis
Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 22+ languages.
No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny